Back to top
more

Corcept Therapeutics (CORT)

(Real Time Quote from BATS)

$34.10 USD

34.10
257,529

+0.22 (0.65%)

Updated Jul 22, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Is (CORT) Outperforming Other Medical Stocks This Year?

Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 5th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sweta Killa headshot

5 Growth ETFs & Stocks Set to Flourish in Spring

Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.

RedHill (RDHL) Soars: Stock Adds 9.2% in Session

RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Corcept Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.

Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock

Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

What's in Store for Corcept (CORT) This Earnings Season?

During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

Catalyst Gives Preliminary Firdapse Estimates & Other Updates

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 7th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can The Uptrend Continue for Corcept Therapeutics?

As of late, it has definitely been a great time to be an investor Corcept Therapeutics.